Cargando…

Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis

BACKGROUND: Although phosphodiesterase-4 (PDE4) inhibitors have been shown to reduce COPD exacerbation rate, their biological mechanism of action is not completely elucidated at the molecular level. We aimed to characterise the whole genome gene expression profile of the inhaled PDE4-inhibitor CHF60...

Descripción completa

Detalles Bibliográficos
Autores principales:	Govoni, Mirco, Bassi, Michele, Vezzoli, Stefano, Lucci, Germano, Emirova, Aida, Nandeuil, Marie Anna, Petruzzelli, Stefano, Jellema, Gera L., Afolabi, Ebenezer K., Colgan, Brendan, Leaker, Brian, Kornmann, Oliver, Beeh, Kai Michael, Watz, Henrik, Singh, Dave
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085203/ https://www.ncbi.nlm.nih.gov/pubmed/32197620 http://dx.doi.org/10.1186/s12931-020-1329-y

Ejemplares similares

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
por: Singh, Dave, et al.
Publicado: (2019)

COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type‐2 and PDE4 gene expression in sputum
por: Singh, Dave, et al.
Publicado: (2020)

COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition
por: Singh, Dave, et al.
Publicado: (2020)

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
por: Singh, Dave, et al.
Publicado: (2020)

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers
por: Mariotti, Fabrizia, et al.
Publicado: (2018)

Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation
por: Jolling, Koen, et al.
Publicado: (2019)

Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus‐inducible cytokines
por: Edwards, Michael R., et al.
Publicado: (2016)

CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice
por: Stellari, Fabio F., et al.
Publicado: (2019)

Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)
por: Beeh, Kai M, et al.
Publicado: (2018)

The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study
por: Singh, Dave, et al.
Publicado: (2017)

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
por: Facchinetti, Fabrizio, et al.
Publicado: (2021)

Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan
por: Tseng, Sung-Pin, et al.
Publicado: (2009)

Electrocardiographic and other Noninvasive Hemodynamic Markers in Decompensated CHF Patients
por: Piccirillo, Gianfranco, et al.
Publicado: (2023)

Effect of GM6001 on the expression of syndecan-1 in rats with acute kidney injury and its protective effect on the kidneys
por: Zhang, Kunying, et al.
Publicado: (2020)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

Synthesis of CHF(2)-substituted 3-azabicyclo[3.1.0]hexanes by photochemical decomposition of CHF(2)-pyrazolines
por: Zheng, Yang, et al.
Publicado: (2018)

The Saccharomyces cerevisiae W303-K6001 cross-platform genome sequence: insights into ancestry and physiology of a laboratory mutt
por: Ralser, Markus, et al.
Publicado: (2012)

Reading Level and Suitability of Congestive Heart Failure (CHF) Education in a Mobile App (CHF Info App): Descriptive Design Study
por: Athilingam, Ponrathi, et al.
Publicado: (2019)

Measuring dobutamine (Db) clearance during continuous hemofiltration (CHF)
por: Van der Linden, T, et al.
Publicado: (1998)

Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011)

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
por: Singh, Dave, et al.
Publicado: (2019)

A Novel Processing-Free Method for RNAseq Analysis of Spontaneous Sputum in Chronic Obstructive Pulmonary Disease
por: Ricci, Francesca, et al.
Publicado: (2021)

Telemedicine Facilitates CHF Home Health Care for Those with Systolic Dysfunction
por: Seibert, Pennie S., et al.
Publicado: (2008)

CRT-D Therapy in Patients with Decompensated NYHA Class-Four CHF
por: Zaeem, Faisal, et al.
Publicado: (2012)

CERN’s light guide sells for 8000 CHF for a good cause
Publicado: (2009)

Acute Effects of Continuous Positive Airway Pressure on Pulse Pressure in CHF
por: Blanco, Jacobo Bacariza, et al.
Publicado: (2015)

Serum Uric Acid level in the severity of Congestive Heart Failure (CHF)
por: khan, Adnan, et al.
Publicado: (2017)

Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype – a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

Crackle Pitch Rises Progressively during Inspiration in Pneumonia, CHF, and IPF Patients
por: Vyshedskiy, Andrey, et al.
Publicado: (2012)

Proposal for the Outsourcing of the Processing of Orders with a Value below 5 000 CHF
Publicado: (1999)

Interval and continuous exercise enhances aerobic capacity and hemodynamic function in CHF rats
por: Nunes, Ramiro B., et al.
Publicado: (2015)

Variability in Physical Activity Assessed with Accelerometer Is an Independent Predictor of Mortality in CHF Patients
por: Melin, Michael, et al.
Publicado: (2016)

A New Paradigm for Understanding and Enhancing the Critical Heat Flux (CHF) Limit
por: Fazeli, Abdolreza, et al.
Publicado: (2017)

Are the measurement properties of incremental exercise tests similar between patients with COPD and CHF?
por: Harvey-Dunstan, Theresa C, et al.
Publicado: (2019)

Evaluation of the HFA‐PEFF Score: results from the prospective DIAST‐CHF cohort
por: Hashemi, Djawid, et al.
Publicado: (2022)

COVID-19 AND HEART FAILURE: THE PANDEMIC'S EFFECT ON CHF HOSPITALIZATION, READMISSION, AND MORTALITY
por: Mignery, Matthew, et al.
Publicado: (2023)

Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)

The Mobilome-Enriched Genome of the Competence-Deficient Streptococcus pneumoniae BM6001, the Original Host of Integrative Conjugative Element Tn5253, Is Phylogenetically Distinct from Historical Pneumococcal Genomes
por: Colombini, Lorenzo, et al.
Publicado: (2023)

Impact of the New Generation Reconstituted Surfactant CHF5633 on Human CD4(+) Lymphocytes
por: Fehrholz, Markus, et al.
Publicado: (2016)

Using text mining techniques to extract phenotypic information from the PhenoCHF corpus
por: Alnazzawi, Noha, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lk8jajgvec3lvu4kkjl2g4pthd